Illumina and Regeneron are taking stakes in health data company Truveta to help fund research that may dwarf the efforts of the National Institutes of Health’s All of Us million-person program ...

Former UFC champions Petr Yan and Aljamain Sterling nodded to their controversial UFC 259 fight in a viral clip. Petr Yan and Aljamain Sterling found mutual respect after sharing the UFC Octagon ...

After Regeneron Chief Scientific Officer George Yancopoulos, M.D., Ph.D., spent more than 25 minutes waxing about the company’s deep pipeline Monday at the J.P. Morgan Healthcare Conference ...

Regeneron stock has trended bearishly since August, but growth in LIBTAYO and DUPIXENT offers a promising outlook, prompting a BUY rating. EYLEA HD's success mitigates biosimilar competition ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other best depressed stocks to invest in now. The US stocks ended 2024 with a ...

Regeneron Pharmaceuticals, Inc. (REGN) Securities Class Action: The litigation is focused on the propriety of Regeneron’s statements about its compliance with applicable rules and regulations ...

Regeneron Pharmaceuticals, Inc. REGN provided business and pipeline updates at the 43rd Annual J.P. Morgan Healthcare Conference. Shares of the company moved up in pre-market trading on Jan. 14 ...

During the last three months, 18 analysts shared their evaluations of Regeneron Pharmaceuticals REGN, revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of ...

NEW YORK, Jan 13 (Reuters) - Medical data research company Truveta said on Monday that Regeneron Pharmaceuticals (REGN.O), opens new tab, Illumina (ILMN.O), opens new ...

Analyst Tim Anderson of Bank of America Securities maintained a Sell rating on Regeneron (REGN – Research Report), with a price target of $565.00. Discover outperforming stocks and invest ...